Professor Sina Dorudi

Professor of Surgical Oncology


Professor Sina Dorudi was formerly the lead Consultant Colorectal Cancer Surgeon at Barts and The London NHS Trust.and Professor of Surgical Oncology at Barts and The London School of Medicine and Dentistry.

Professor Dorudi’s major clinical interests are the surgical treatment of colorectal cancer and pelvic surgery. Professor Dorudi directed a nationally and internationally funded research programme, comprising clinical research fellows and scientists focused on the prediction of tumour biology employing DNA microarrays and the investigation and augmentation of the host immune response in colorectal cancer patients. His research work has been awarded a number of national prizes.

Professor Dorudi is a well established postgraduate trainer in pelvic surgery and has developed a multimedia training platform for laparoscopic colorectal; surgery for surgical trainees.

Professor Dorudi is a Member of the Association of Coloproctology of Great Britain & Ireland

Professional background


Professor Dorudi qualified at St Mary’s Hospital, and subsequently training in general and colorectal surgery in Oxford and London. He also undertook a specialist colorectal fellowship in Sydney, Australia to obtain particular expertise in bowel cancer surgery.

Professor Dorudi has a PhD from his research fellowship with Cancer Research UK on the molecular biology of colorectal cancer. He is currently the Medical Director of The Princess Grace Hospital.

Services provided to HCA
Professor Dorudi provides medical advisory services for HCA's The Princess Grace Hospital. In his role, Professor Dorudi leads interactions with hospital medical staff and the hospital leadership team to assist the hospital by providing medical advice and promote high quality, cost effective care.

In his role, he contributes to the strategy, policies and decision making regarding general surgery treatments and advises HCA to ensure that care provided within the facility is appropriate and efficient. In his role, Professor Dorudi advises on initiatives to drive clinical standards by providing professional advice on clinical governance matters and ensuring the adoption of those by colleagues in the general surgery area.

In addition, he works with medical insurance companies, GPs, other relevant local NHS contacts, and patients to educate and advise on relevant clinical updates to treatments in general surgery available in the facility. Furthermore, he advises on the accuracy of literature that may be published regarding relevant services. He will also advise on how to make the patient referral smooth to reduce stress and anxiety for patients.

As well as promoting successful working of the facility's Medical Advisory Committee, Integrated Governance Committee and advising the hospital's senior management team on all matters relating to medical practice within the facility, Professor Dorudi is responsible for providing advice on clinical governance matters to conform with national standards and recommend new programmes to drive up clinical standards.

In addition, he supports the HCA team to recruit and retain staff as well as taking a lead role in medical staff credentialing. In his role, he will evaluate ongoing quality initiatives such as clinical audits and quality assurance programmes.

Professor Dorudi leads the facility's multi-disciplinary team, bringing together our clinical teams, to discuss the quality of our care and decide the most appropriate treatment pathways for our patients.

Professor Dorudi is the "Lead Clinician" for the colorectal surgery service and as such will represent the Centre at medical conferences and other local, national or international meetings with clinical and academic experts.

HCA UK is charged by doctors in return for their expertise and advice, including on how to operate safe hospital facilities delivering complex care. All services provided under this agreement are charged to HCA UK. From January to December 2017, the total charge was £116,667

The information disclosed on this page in accordance with the Private Healthcare Market Investigation Order 2014 is true and accurate to the best of HCA’s knowledge and belief.